HDAC inhibitors have recently been studied as a new group of anti-cancer epigenetic treatment tools, and a HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), is FDA approved for the treatment of cutaneous T cell lymphoma [15]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.